R01CA262540
Project Grant
Overview
Grant Description
Understanding the Role of Structural Racism on Racial/Ethnic Inequities in Lung Cancer Risk - Abstract
Despite the overall progress in lowering the prevalence of cigarette smoking and incidence rates of lung cancer in the U.S., the persistent racial/ethnic and socioeconomic (SES) inequities in the burden of lung cancer are major public health problems.
Over decades, African Americans and Native Hawaiians have suffered a disproportionate incidence of lung cancer in comparison to other racial/ethnic groups. The concerning observation that African Americans and Native Hawaiians experience a higher risk of lung cancer, compared to European, Japanese, and Latin Americans, for the same lifetime exposure to smoking has fueled molecular epidemiology studies of smoking and lung cancer to investigate racial/ethnic differences in genetic susceptibility, biomarkers of smoking, and epigenetics.
While these studies have shed light on the contribution of molecular factors to racial/ethnic differences in lung cancer risk, both molecular, genetic, and individual-level lifestyle factors are unable to account fully for the racial/ethnic differences in lung cancer risk. Thus, there is a clear need to address how upstream factors of social determinants of health, including structural racism, influence lung cancer inequities.
To address this gap, we will leverage the unique epidemiological resources of the Multiethnic Cohort Study and Southern Community Cohort Study. These two large cohorts include over 272,000 well-characterized adult participants with up to 27 years of follow-up and high-quality cancer surveillance data.
Specifically, we will assess the impact of structural racism and neighborhood disinvestment on: change in smoking status and internal smoking dose (Aim 1); racial/ethnic and SES inequities in lung cancer risk (Aim 2); and DNA methylation in blood leukocytes (Aim 3). In addition, we will evaluate whether air pollution mediates the relationships between structural racism and lung cancer inequities. We will also assess whether DNA methylated sites and epigenetic age mediate the association between structural racism and lung cancer risk (Aim 3).
The strengths of this proposal include: 1) the integration of two population-based cohorts, statistically powered to study five racial/ethnic groups from urban and rural settings, ensuring the representation of understudied high-risk populations; 2) the public health significance of addressing the influence of structural racism on smoking and lung cancer inequities; 3) the assessment of the biological pathways by which structural racism is embodied and leads to lung cancer inequities.
Findings from this proposal will expand our understanding of the contribution of structural racism to lung cancer development and the underlying biological pathways by which structural racism may operate. This knowledge has translational relevance in providing empirical evidence for community stakeholders, policymakers, and implementation scientists to develop interventions for smoking and lung cancer that also may have broad health benefits.
Despite the overall progress in lowering the prevalence of cigarette smoking and incidence rates of lung cancer in the U.S., the persistent racial/ethnic and socioeconomic (SES) inequities in the burden of lung cancer are major public health problems.
Over decades, African Americans and Native Hawaiians have suffered a disproportionate incidence of lung cancer in comparison to other racial/ethnic groups. The concerning observation that African Americans and Native Hawaiians experience a higher risk of lung cancer, compared to European, Japanese, and Latin Americans, for the same lifetime exposure to smoking has fueled molecular epidemiology studies of smoking and lung cancer to investigate racial/ethnic differences in genetic susceptibility, biomarkers of smoking, and epigenetics.
While these studies have shed light on the contribution of molecular factors to racial/ethnic differences in lung cancer risk, both molecular, genetic, and individual-level lifestyle factors are unable to account fully for the racial/ethnic differences in lung cancer risk. Thus, there is a clear need to address how upstream factors of social determinants of health, including structural racism, influence lung cancer inequities.
To address this gap, we will leverage the unique epidemiological resources of the Multiethnic Cohort Study and Southern Community Cohort Study. These two large cohorts include over 272,000 well-characterized adult participants with up to 27 years of follow-up and high-quality cancer surveillance data.
Specifically, we will assess the impact of structural racism and neighborhood disinvestment on: change in smoking status and internal smoking dose (Aim 1); racial/ethnic and SES inequities in lung cancer risk (Aim 2); and DNA methylation in blood leukocytes (Aim 3). In addition, we will evaluate whether air pollution mediates the relationships between structural racism and lung cancer inequities. We will also assess whether DNA methylated sites and epigenetic age mediate the association between structural racism and lung cancer risk (Aim 3).
The strengths of this proposal include: 1) the integration of two population-based cohorts, statistically powered to study five racial/ethnic groups from urban and rural settings, ensuring the representation of understudied high-risk populations; 2) the public health significance of addressing the influence of structural racism on smoking and lung cancer inequities; 3) the assessment of the biological pathways by which structural racism is embodied and leads to lung cancer inequities.
Findings from this proposal will expand our understanding of the contribution of structural racism to lung cancer development and the underlying biological pathways by which structural racism may operate. This knowledge has translational relevance in providing empirical evidence for community stakeholders, policymakers, and implementation scientists to develop interventions for smoking and lung cancer that also may have broad health benefits.
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
San Francisco,
California
94143
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 349% from $714,588 to $3,210,007.
San Francisco Regents Of The University Of California was awarded
Structural Racism & Lung Cancer Inequities: Epidemiological Study
Project Grant R01CA262540
worth $3,210,007
from National Cancer Institute in July 2022 with work to be completed primarily in San Francisco California United States.
The grant
has a duration of 5 years and
was awarded through assistance program 93.393 Cancer Cause and Prevention Research.
The Project Grant was awarded through grant opportunity NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 6/22/26
Period of Performance
7/1/22
Start Date
6/30/27
End Date
Funding Split
$3.2M
Federal Obligation
$0.0
Non-Federal Obligation
$3.2M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for R01CA262540
Transaction History
Modifications to R01CA262540
Additional Detail
Award ID FAIN
R01CA262540
SAI Number
R01CA262540-3364460920
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NC00 NIH National Cancer Institute
Funding Office
75NC00 NIH National Cancer Institute
Awardee UEI
KMH5K9V7S518
Awardee CAGE
4B560
Performance District
CA-11
Senators
Dianne Feinstein
Alejandro Padilla
Alejandro Padilla
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Cancer Institute, National Institutes of Health, Health and Human Services (075-0849) | Health research and training | Grants, subsidies, and contributions (41.0) | $1,361,074 | 100% |
Modified: 6/22/26